Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.45 Insider Own14.54% Shs Outstand35.12M Perf Week5.16%
Market Cap343.82M Forward P/E62.49 EPS next Y0.16 Insider Trans1.56% Shs Float30.01M Perf Month-24.28%
Income-14.21M PEG- EPS next Q-0.04 Inst Own70.96% Short Float / Ratio20.35% / 8.90 Perf Quarter-41.06%
Sales114.17M P/S3.01 EPS this Y-1.31% Inst Trans-4.64% Short Interest6.11M Perf Half Y-51.68%
Book/sh2.16 P/B4.54 EPS next Y130.32% ROA-7.38% Target Price28.13 Perf Year-19.02%
Cash/sh2.10 P/C4.65 EPS next 5Y15.00% ROE-36.92% 52W Range7.60 - 28.25 Perf YTD-33.67%
Dividend- P/FCF- EPS past 5Y3.03% ROI-5.37% 52W High-65.35% Beta0.41
Dividend %- Quick Ratio5.33 Sales past 5Y28.85% Gross Margin69.78% 52W Low28.82% ATR0.60
Employees217 Current Ratio5.80 Sales Q/Q50.13% Oper. Margin3.09% RSI (14)41.51 Volatility3.53% 6.50%
OptionableYes Debt/Eq2.50 EPS Q/Q45.77% Profit Margin-12.44% Rel Volume0.70 Prev Close9.64
ShortableYes LT Debt/Eq2.49 EarningsNov 13 AMC Payout- Avg Volume686.02K Price9.79
Recom1.00 SMA201.16% SMA50-21.12% SMA200-44.97% Volume483,386 Change1.56%
Date Action Analyst Rating Change Price Target Change
Sep-08-22Resumed B. Riley Securities Buy $17
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
Nov-29-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
08:00AM Loading…
Oct-30-23 08:00AM
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
Aug-09-23 04:14PM
Jul-31-23 07:00AM
02:56PM Loading…
Jul-28-23 02:56PM
Jul-26-23 03:42PM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
Jul-18-23 05:00PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
11:57AM Loading…
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
May-11-23 05:15PM
May-08-23 12:07PM
May-04-23 08:00AM
May-03-23 06:44AM
May-02-23 04:42PM
May-01-23 08:50AM
Apr-28-23 06:00PM
Apr-27-23 08:05AM
Apr-24-23 08:43AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Jan-21-23 07:33AM
Jan-18-23 08:50AM
Jan-05-23 07:00AM
Dec-25-22 07:24AM
Dec-21-22 09:21AM
Dec-16-22 07:00AM
Dec-14-22 03:24PM
Nov-30-22 08:00AM
Nov-16-22 05:06AM
Nov-14-22 04:05PM
Nov-10-22 08:00AM
Oct-28-22 08:00AM
Oct-27-22 08:00AM
Oct-13-22 09:35AM
Oct-06-22 03:23PM
Oct-05-22 05:35PM
Sep-29-22 07:00AM
Sep-28-22 07:09AM
Sep-27-22 01:50PM
Sep-21-22 06:01PM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAUM MARK LChief Executive OfficerNov 16Buy8.117,50060,8252,022,961Nov 16 04:45 PM
Opaleye Management Inc.10% OwnerNov 15Buy8.0325,000200,7353,645,000Nov 16 04:05 PM
Opaleye Management Inc.10% OwnerSep 20Buy14.495,98386,7103,620,000Sep 20 06:39 PM
Opaleye Management Inc.10% OwnerSep 19Buy14.6514,017205,3663,614,017Sep 20 06:39 PM
Makary Martin A.DirectorAug 14Buy16.9220,000338,40045,000Aug 15 07:30 AM
BAUM MARK LChief Executive OfficerAug 14Buy17.055,80098,8902,015,461Aug 15 07:30 AM
BAUM MARK LChief Executive OfficerApr 03Option Exercise8.99180,0001,618,2001,664,962Apr 04 07:54 PM
BOLL ANDREW R.Chief Financial OfficerMar 31Option Exercise6.0090,000540,000358,461Apr 04 07:50 PM
BAUM MARK LChief Executive OfficerDec 22Buy13.3925,000334,7501,432,141Dec 23 07:03 AM
BOLL ANDREW R.Chief Financial OfficerDec 22Buy13.542,50033,850255,063Dec 23 07:02 AM
Van Horn R. LawrenceDirectorDec 22Buy13.421,86024,9611,860Dec 23 07:00 AM
Makary Martin A.DirectorDec 21Buy13.3725,000334,25025,000Dec 23 07:01 AM
Opaleye Management Inc.10% OwnerDec 14Buy10.52431,1834,536,0453,600,000Dec 14 04:05 PM
Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
TCON TRACON Pharmaceuticals Inc daily Stock Chart
Index- P/E- EPS (ttm)-0.58 Insider Own15.21% Shs Outstand31.14M Perf Week-7.01%
Market Cap5.86M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float26.41M Perf Month18.80%
Income-11.02M PEG- EPS next Q-0.10 Inst Own29.64% Short Float / Ratio7.62% / 0.47 Perf Quarter-14.41%
Sales9.00M P/S0.65 EPS this Y59.95% Inst Trans-0.06% Short Interest2.01M Perf Half Y-68.14%
Book/sh-0.10 P/B- EPS next Y10.18% ROA-75.82% Target Price4.00 Perf Year-86.65%
Cash/sh0.25 P/C0.76 EPS next 5Y- ROE-1277.01% 52W Range0.13 - 2.19 Perf YTD-87.36%
Dividend- P/FCF- EPS past 5Y34.33% ROI- 52W High-91.40% Beta1.00
Dividend %- Quick Ratio0.71 Sales past 5Y-53.15% Gross Margin99.83% 52W Low50.04% ATR0.03
Employees18 Current Ratio0.71 Sales Q/Q- Oper. Margin-145.97% RSI (14)49.65 Volatility10.34% 17.16%
OptionableYes Debt/Eq- EPS Q/Q197.43% Profit Margin-122.49% Rel Volume0.29 Prev Close0.20
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume4.31M Price0.19
Recom1.67 SMA20-2.07% SMA507.85% SMA200-69.84% Volume1,242,176 Change-5.85%
Date Action Analyst Rating Change Price Target Change
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Nov-21-23 07:55AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
Nov-12-23 08:47AM
07:45AM Loading…
Nov-10-23 07:45AM
Nov-09-23 04:58PM
Oct-31-23 04:02PM
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
Aug-15-23 08:43AM
Aug-14-23 07:00PM
04:05PM Loading…
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
May-11-23 11:24AM
May-10-23 04:38PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
Mar-10-23 02:26AM
05:49AM Loading…
Mar-09-23 05:49AM
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
Oct-31-22 08:00AM
Oct-06-22 08:30AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
Aug-10-22 04:02PM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
Jul-28-21 08:05AM
Jul-21-21 10:30PM
Jul-20-21 08:05AM
Jun-30-21 08:05AM
Jun-29-21 08:05AM
Jun-28-21 01:04PM
Jun-18-21 10:08AM
Jun-04-21 09:01AM
Jun-01-21 08:05AM
May-25-21 08:05AM
May-20-21 08:05AM
May-05-21 04:03PM
May-03-21 08:05AM
Apr-28-21 08:05AM
Apr-26-21 08:00AM
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THEUER CHARLESPresident and CEOApr 27Buy0.7547,00035,250399,417Apr 28 06:00 AM
THEUER CHARLESPresident and CEOApr 26Buy0.663,9992,639352,417Apr 28 06:00 AM
Opaleye Management Inc.10% OwnerMar 09Buy1.38174,508240,8214,324,508Mar 13 04:05 PM
THEUER CHARLESPresident and CEOMar 01Buy1.524,8007,296344,918Mar 02 06:24 AM
THEUER CHARLESPresident and CEOFeb 28Buy1.52200304340,118Mar 02 06:24 AM
THEUER CHARLESPresident and CEOJan 18Buy1.626,80011,016339,918Jan 19 06:05 AM
Brown Scott B.Chief Financial OfficerDec 29Buy1.493,5005,21521,628Jan 03 06:00 AM
LARUE WILLIAM RDirectorDec 21Sale1.261201517,763Jan 19 06:00 AM
Opaleye Management Inc.10% OwnerDec 14Buy1.25167,500209,8764,150,000Dec 16 05:03 PM
THEUER CHARLESPresident and CEODec 14Buy1.2923,00029,755333,118Dec 15 06:00 AM
Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
TARA Protara Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-6.13 Insider Own25.64% Shs Outstand11.27M Perf Week11.50%
Market Cap18.18M Forward P/E- EPS next Y-3.84 Insider Trans0.00% Shs Float8.45M Perf Month34.45%
Income-69.17M PEG- EPS next Q-0.92 Inst Own37.02% Short Float / Ratio0.57% / 1.37 Perf Quarter-24.53%
Sales0.00M P/S- EPS this Y39.04% Inst Trans-4.78% Short Interest0.05M Perf Half Y-42.24%
Book/sh6.77 P/B0.24 EPS next Y-7.50% ROA-58.35% Target Price30.60 Perf Year-53.35%
Cash/sh6.52 P/C0.25 EPS next 5Y- ROE-64.00% 52W Range1.04 - 4.18 Perf YTD-40.30%
Dividend- P/FCF- EPS past 5Y41.46% ROI-84.67% 52W High-61.72% Beta1.49
Dividend %- Quick Ratio11.49 Sales past 5Y0.00% Gross Margin- 52W Low53.85% ATR0.13
Employees25 Current Ratio11.49 Sales Q/Q- Oper. Margin0.00% RSI (14)66.22 Volatility8.74% 9.37%
OptionableYes Debt/Eq0.07 EPS Q/Q-27.27% Profit Margin- Rel Volume2.24 Prev Close1.37
ShortableYes LT Debt/Eq0.06 EarningsNov 03 BMO Payout- Avg Volume35.20K Price1.60
Recom1.00 SMA2025.29% SMA5014.08% SMA200-34.55% Volume78,954 Change16.79%
Date Action Analyst Rating Change Price Target Change
Jul-10-23Resumed Guggenheim Buy $22
Jun-04-21Initiated H.C. Wainwright Buy $40
Feb-17-21Initiated Oppenheimer Outperform $43
Oct-19-20Initiated Cowen Outperform $50
Jul-29-20Initiated Guggenheim Buy $50
Nov-30-23 08:30AM
Nov-03-23 09:43AM
Oct-23-23 08:00AM
Sep-20-23 08:30AM
07:30AM Loading…
Sep-05-23 07:30AM
Aug-03-23 08:00AM
May-15-23 08:00AM
May-04-23 08:00AM
May-02-23 08:00AM
Apr-28-23 08:00AM
Mar-08-23 08:00AM
Mar-01-23 08:00AM
Feb-02-23 08:00AM
Jan-30-23 08:00AM
08:00AM Loading…
Dec-01-22 08:00AM
Nov-03-22 08:00AM
Oct-24-22 08:35AM
Sep-06-22 08:00AM
Aug-09-22 08:00AM
Jun-21-22 08:00AM
May-26-22 05:11PM
May-17-22 08:00AM
May-12-22 08:00AM
May-05-22 08:00AM
Apr-11-22 09:55AM
Mar-24-22 08:00AM
Mar-23-22 10:00AM
Mar-09-22 07:30AM
05:50AM Loading…
Mar-08-22 05:50AM
Mar-02-22 08:00AM
Feb-01-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-08-21 11:15AM
Nov-04-21 08:00AM
Oct-25-21 04:45PM
Oct-12-21 07:00AM
Sep-17-21 04:05PM
Sep-13-21 07:00AM
Sep-09-21 10:31AM
Sep-07-21 08:00AM
Aug-05-21 08:00AM
Jul-07-21 08:00AM
Jun-22-21 07:30AM
Jun-10-21 08:00AM
May-13-21 08:00AM
May-06-21 07:30AM
Apr-23-21 07:00AM
Apr-19-21 04:09PM
Apr-12-21 11:12AM
Mar-30-21 07:01AM
Mar-11-21 07:30AM
Mar-10-21 08:00AM
Feb-04-21 08:00AM
Feb-02-21 08:00AM
Dec-16-20 11:07PM
Dec-07-20 04:30PM
Dec-03-20 07:00AM
Nov-24-20 07:00AM
Nov-12-20 07:15AM
Nov-11-20 07:00AM
Nov-04-20 07:00AM
Sep-28-20 03:12PM
Sep-22-20 08:13AM
Sep-21-20 04:01PM
Sep-08-20 07:00AM
Sep-02-20 05:49PM
Aug-03-20 07:00AM
Jul-28-20 07:00AM
Jul-24-20 07:00AM
Jul-03-20 06:34PM
Jul-02-20 07:59PM
Jun-02-20 04:05PM
May-26-20 08:30AM
May-13-20 08:00AM
May-11-20 08:38AM
May-05-20 04:05PM
Apr-02-20 07:00AM
Feb-11-20 08:00AM
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
TELA TELA Bio Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.06 Insider Own30.50% Shs Outstand19.17M Perf Week-1.77%
Market Cap135.67M Forward P/E- EPS next Y-1.52 Insider Trans0.32% Shs Float17.02M Perf Month-4.48%
Income-43.75M PEG- EPS next Q-0.42 Inst Own62.62% Short Float / Ratio4.24% / 4.58 Perf Quarter-37.89%
Sales53.08M P/S2.56 EPS this Y29.49% Inst Trans17.69% Short Interest0.72M Perf Half Y-49.91%
Book/sh1.25 P/B4.44 EPS next Y20.75% ROA-52.44% Target Price14.40 Perf Year-42.17%
Cash/sh2.38 P/C2.33 EPS next 5Y- ROE-162.49% 52W Range4.23 - 13.18 Perf YTD-51.83%
Dividend- P/FCF- EPS past 5Y-2.37% ROI-61.70% 52W High-57.97% Beta0.93
Dividend %- Quick Ratio4.43 Sales past 5Y60.37% Gross Margin69.08% 52W Low30.82% ATR0.33
Employees173 Current Ratio5.36 Sales Q/Q34.89% Oper. Margin-77.69% RSI (14)52.35 Volatility6.47% 6.54%
OptionableYes Debt/Eq1.33 EPS Q/Q30.00% Profit Margin-82.43% Rel Volume0.61 Prev Close5.43
ShortableYes LT Debt/Eq1.32 EarningsNov 09 AMC Payout- Avg Volume157.56K Price5.54
Recom1.00 SMA209.57% SMA50-5.00% SMA200-37.66% Volume96,233 Change2.03%
Date Action Analyst Rating Change Price Target Change
May-31-22Initiated Lake Street Buy $17
Dec-03-19Initiated Piper Jaffray Overweight
Dec-03-19Initiated JMP Securities Mkt Outperform
Dec-03-19Initiated Jefferies Buy
Dec-03-19Initiated Canaccord Genuity Buy
Dec-05-23 07:00AM
Nov-16-23 07:00AM
Nov-12-23 12:20PM
Nov-10-23 04:05PM
Nov-09-23 04:05PM
07:00AM Loading…
Oct-26-23 07:00AM
Sep-18-23 04:05PM
Aug-16-23 07:00AM
Aug-11-23 10:03AM
Aug-10-23 09:18AM
Aug-09-23 06:05PM
Aug-04-23 04:02PM
Jul-26-23 07:00AM
Jul-06-23 10:09AM
07:51PM Loading…
Jun-18-23 07:51PM
Jun-15-23 07:00AM
May-25-23 07:00AM
May-21-23 10:30AM
May-19-23 07:00AM
May-12-23 07:44AM
May-11-23 05:25PM
May-09-23 07:00AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-30-23 08:26AM
Apr-28-23 06:47PM
Apr-27-23 07:00AM
11:00PM Loading…
Apr-18-23 11:00PM
Apr-03-23 06:14AM
Mar-29-23 07:00AM
Mar-24-23 07:15AM
Mar-23-23 07:00AM
Mar-22-23 06:01AM
Mar-21-23 05:15PM
Mar-16-23 07:00AM
Feb-28-23 07:00AM
Feb-24-23 04:02PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Jan-20-23 04:05PM
Jan-09-23 07:00AM
Dec-23-22 05:46AM
Dec-21-22 07:00AM
Dec-09-22 04:02PM
Nov-21-22 07:00AM
Nov-12-22 07:42AM
Nov-09-22 05:25PM
Nov-03-22 07:00AM
Oct-28-22 04:05PM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-24-22 10:24AM
Sep-01-22 07:00AM
Aug-23-22 04:01PM
Aug-19-22 10:52AM
Aug-18-22 04:01PM
Aug-16-22 12:01PM
Aug-15-22 10:20PM
Aug-10-22 10:30PM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-29-22 04:01PM
Jul-27-22 07:00AM
Jul-20-22 07:00AM
Jul-08-22 06:45AM
Jun-24-22 08:52AM
Jun-23-22 11:02AM
Jun-10-22 06:15AM
Jun-02-22 07:00AM
May-31-22 07:00AM
May-26-22 07:00AM
May-17-22 08:25AM
May-10-22 05:45PM
May-09-22 07:00AM
May-05-22 05:55PM
May-02-22 04:11AM
Apr-29-22 05:00PM
Apr-26-22 07:00AM
Apr-18-22 07:00AM
Mar-30-22 07:00AM
Mar-21-22 05:15PM
Mar-16-22 07:00AM
Mar-08-22 12:42PM
Mar-07-22 04:01PM
Mar-03-22 08:35AM
Feb-28-22 05:45PM
Feb-25-22 04:01PM
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Firestone Gregory A.Chief Business OfficerDec 05Buy5.652,60014,68835,511Dec 07 04:02 PM
KOBLISH ANTONYChief Executive OfficerNov 14Buy4.5411,00049,976303,634Nov 14 08:01 PM
Cuca RobertoCOO and CFONov 14Buy4.4910,00044,93862,371Nov 14 08:02 PM
ORBIMED ADVISORS LLC10% OwnerApr 21Sale9.4127,700260,6572,835,542Apr 21 05:08 PM
ORBIMED ADVISORS LLC10% OwnerApr 20Sale9.4328,300266,8692,863,242Apr 21 05:08 PM
ORBIMED ADVISORS LLC10% OwnerApr 19Sale9.30136,0001,264,8002,891,542Apr 21 05:08 PM
Burgess Vincent JDirectorMar 29Option Exercise4.444,86021,5787,995Mar 31 04:32 PM
Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
ETON Eton Pharmaceuticals Inc daily Stock Chart
Index- P/E42.50 EPS (ttm)0.08 Insider Own12.69% Shs Outstand25.35M Perf Week-2.70%
Market Cap92.38M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float22.40M Perf Month-19.10%
Income2.23M PEG- EPS next Q- Inst Own26.89% Short Float / Ratio3.36% / 5.90 Perf Quarter-30.64%
Sales32.83M P/S2.81 EPS this Y- Inst Trans6.66% Short Interest0.75M Perf Half Y-6.98%
Book/sh0.66 P/B5.47 EPS next Y- ROA8.42% Target Price10.00 Perf Year22.03%
Cash/sh0.86 P/C4.19 EPS next 5Y- ROE15.90% 52W Range2.42 - 5.81 Perf YTD27.66%
Dividend- P/FCF9.98 EPS past 5Y6.23% ROI10.56% 52W High-38.04% Beta1.16
Dividend %- Quick Ratio2.51 Sales past 5Y11156.18% Gross Margin72.47% 52W Low48.76% ATR0.20
Employees28 Current Ratio2.61 Sales Q/Q118.33% Oper. Margin5.68% RSI (14)43.47 Volatility4.12% 5.89%
OptionableYes Debt/Eq0.35 EPS Q/Q81.25% Profit Margin6.80% Rel Volume0.09 Prev Close3.63
ShortableYes LT Debt/Eq0.25 EarningsNov 09 AMC Payout- Avg Volume127.79K Price3.60
Recom1.00 SMA20-2.25% SMA50-7.86% SMA200-5.71% Volume11,525 Change-0.83%
Date Action Analyst Rating Change Price Target Change
Oct-14-21Resumed B. Riley Securities Buy $10
Jan-04-21Reiterated H.C. Wainwright Buy $20 → $15
Sep-20-19Initiated B. Riley FBR Buy $13.50
Jun-10-19Initiated H.C. Wainwright Buy $15
Nov-11-23 11:09AM
Nov-09-23 04:01PM
Oct-30-23 06:50AM
Oct-23-23 05:16AM
Oct-18-23 08:00AM
06:50AM Loading…
Oct-04-23 06:50AM
Sep-22-23 12:04PM
Sep-20-23 09:40AM
Sep-12-23 08:50AM
Aug-25-23 11:36AM
Aug-23-23 06:50AM
Aug-16-23 09:15AM
Aug-13-23 07:52AM
Aug-11-23 12:44PM
Aug-10-23 05:40PM
04:01PM Loading…
Aug-08-23 10:50AM
Aug-01-23 04:05PM
Jul-17-23 04:05PM
Jul-15-23 08:40AM
Jun-28-23 06:50AM
May-16-23 11:35AM
May-11-23 05:35PM
May-10-23 06:50AM
May-03-23 04:05PM
Apr-19-23 11:22AM
Mar-22-23 07:17AM
Mar-18-23 02:03AM
Mar-16-23 05:25PM
04:01PM Loading…
Mar-15-23 06:50AM
Mar-07-23 04:05PM
Feb-08-23 12:00PM
Feb-05-23 07:30AM
Jan-31-23 08:00AM
Jan-25-23 10:00AM
Jan-24-23 12:26PM
Jan-23-23 11:01AM
Jan-12-23 10:34AM
Jan-11-23 07:27AM
Nov-23-22 12:37PM
Nov-22-22 12:45PM
Nov-16-22 10:33AM
Nov-10-22 05:45PM
Nov-02-22 04:05PM
Oct-18-22 04:05PM
Sep-27-22 09:05AM
Sep-13-22 09:00AM
Aug-30-22 04:05PM
Aug-11-22 05:35PM
Aug-08-22 10:00AM
Aug-04-22 10:00AM
Aug-02-22 08:00AM
Jul-18-22 08:09AM
Jun-24-22 09:45AM
Jun-13-22 12:28PM
May-13-22 09:08AM
May-12-22 05:15PM
May-10-22 05:45PM
May-05-22 07:25PM
May-03-22 04:02PM
Apr-12-22 10:03AM
Apr-11-22 04:01PM
Mar-16-22 04:02PM
Mar-14-22 07:00AM
Mar-10-22 05:25PM
Mar-08-22 08:00AM
Jan-10-22 05:19AM
Dec-20-21 07:30AM
Nov-26-21 04:43AM
Nov-18-21 02:04PM
Nov-15-21 06:45PM
Nov-08-21 08:29AM
Nov-04-21 03:01PM
Nov-03-21 04:15PM
Oct-28-21 07:30AM
Oct-12-21 07:14AM
Aug-16-21 05:25PM
Aug-04-21 03:00PM
Aug-03-21 04:05PM
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.